Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Pyxis Oncology, Inc. (PYXS) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/11/2023 8-K Quarterly results
Docs: "Pyxis Oncology Reports Financial Results for Second-Quarter 2023 and Provides Corporate Update Third dose cohort initiated in Phase 1 trial of PYX-201, Pyxis Oncology's first ADC product candidate Preliminary data from two Phase 1 trials on track for late 2023 to early 2024 Apexigen transaction anticipated to close later in August Strong balance sheet with $144 million in cash and short-term investments supports operations into 1H 2025 BOSTON, August 11, 2023 – Pyxis Oncology, Inc. , a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, today reported financial results for the quarter ended June 30, 2023, and provided a corporate update. Pyxis Oncology ended the second quarter of 2023 with approximately $144.1 million in cash, cas..."
05/11/2023 8-K Quarterly results
Docs: "Pyxis Oncology Reports Financial Results for the First Quarter 2023 and Provides Corporate Update Orphan Drug Designation received for PYX-201 in pancreatic cancer Preliminary data from two Phase 1 trials anticipated late 2023 to early 2024 Strong balance sheet with $150.8 million in cash and short-term investments and no debt supports operations into 1H 2025 BOSTON, Mass., May 11, 2023 – Pyxis Oncology, Inc. , a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, today reported financial results for the quarter ended March 31, 2023, and provided a corporate update. Pyxis Oncology ended the first quarter of 2023 with approximately $150.8 million in cash, cash equivalents, restricted cash and short-term investments, which is expect..."
11/01/2022 8-K Quarterly results
Docs: "Pyxis Oncology Reports Financial Results for the Quarter Ended September 30, 2022 and Provides Corporate Update • Expands worldwide licensing agreement with Pfizer to obtain additional antibody-drug conjugate platform components • Gains exclusive rights to Pfizer’s ADC technology platform and toolkit to certain licensed targets; Initial multi-target sublicense deal executed with stealth ADC company • Remains on track with IND plans for PYX-106 and PYX-201 by the end of this year • Strong balance sheet with $200 million in cash as of September 30, 2022 maintains flexibility to pursue business development opportunities CAMBRIDGE, Mass., November 1, 2022 –"
08/15/2022 8-K Quarterly results
05/13/2022 8-K Quarterly results
11/15/2021 8-K Quarterly results
Docs: "Pyxis Reports Financial Results for the Third Quarter of 2021 and Provides Business Update CAMBRIDGE, Mass., Nov. 15, 2021 – Pyxis Oncology, Inc. , a preclinical oncology company focused on developing next-generation therapeutics for difficult to treat cancers, today reported financial results for its third quarter ended September 30, 2021 and provided a business update. “Our initial public offering was a tremendous milestone for Pyxis, allowing us to debut as a public company with a strong balance sheet well positioned to advance our lead programs toward the clinic,” said Lara Sullivan, M.D., Chief Executive Officer of Pyxis. “We are on track to submit Investigational New Drug applications for PYX-201 and PYX-202 by mid-2022, and for PYX-203 by 2023. With the resource..."

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy